Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Summary

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.

Timeline

Start

2023-09-05

Primary completion

2026-04-30

Completion

2026-04-30

Publications

• Comitre-Mariano B, Segura-Collar B, Vellila-Alonso G, Contreras R, Hernandez-Lain A, Valiente M, Sepulveda JM, Marcus SG, Garcia-Posadas G, Jimenez-Roldan L, Perez-Nunez A, Gargini R. S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture. Theranostics. 2025 Jan 1;15(2):726-744. doi: 10.7150/thno.100638. eCollection 2025.

Drugs

Indications